Core Viewpoint - The launch of Rebio Biotech on the Hong Kong Stock Exchange marks a significant entry into the Chinese innovative drug industry, particularly in the small RNA field, with a share price set at HKD 57.97 and a listing date of January 9, 2026. The company has attracted notable institutional investors, indicating strong market interest [1][2]. Group 1: Industry Context - The global pharmaceutical innovation is transitioning into the "nucleic acid era," with small RNA drugs emerging as a disruptive treatment paradigm, following small molecules and antibody drugs [1]. - The industry is at a critical turning point, moving from "scientific breakthroughs" to "commercial realization," particularly in the siRNA sector [3]. Group 2: Company Positioning - Rebio Biotech is one of the few companies globally with comprehensive self-research capabilities in small RNA drugs, covering the entire process from target discovery to clinical development [1]. - The company has established a fully autonomous research and production platform, positioning itself to compete internationally and define new treatment standards [1][6]. Group 3: Product Pipeline and Validation - The company’s core products, RBD4059 and RBD5044, are strategically positioned in validated therapeutic areas, reducing development risks and enhancing commercial prospects [10][11]. - RBD4059 targets coagulation factor XI (FXI) and aims to transform anticoagulation therapy, while RBD5044 targets APOC3 for treating hypertriglyceridemia, benefiting from established regulatory pathways [10][11]. Group 4: Technological and Operational Strengths - Rebio's proprietary delivery systems, such as RiboGalSTAR™, have been clinically validated, providing a competitive edge and expanding the application of siRNA therapies beyond liver diseases [9]. - The company has established a clinical trial base in Sweden, ensuring compliance with international standards and facilitating entry into major markets [13]. Group 5: Financial Performance and Growth Potential - The company reported a revenue of CNY 104 million in the first half of 2025, a year-on-year increase of 56.57%, with a reduction in losses by 30.94%, indicating accelerating commercialization capabilities [6]. - The upcoming IPO funding will primarily support global clinical research for core products and enhance technology platform development, facilitating the transition from clinical to commercial stages [18][20]. Group 6: Strategic Collaborations - Rebio has secured strategic partnerships with leading pharmaceutical companies, which not only provide funding but also validate its technological capabilities [14]. - The company retains rights to overseas markets in its licensing agreements, highlighting its focus on global value realization [14]. Group 7: Future Outlook - The dual strategy of advancing proprietary products and engaging in platform licensing is expected to create a sustainable revenue model, enhancing financial stability and supporting ongoing research [17][18]. - Rebio Biotech is positioned for a systematic value reassessment as it combines technology, product pipeline, and international operational capabilities, making it a unique player in the biotechnology sector [20].

Group 1 - Rebio Biopharma-B (6938.HK) has officially launched its IPO, planning to globally offer 27.4874 million H-shares at a price of HKD 57.97 per share, with the subscription period from December 31, 2025, to January 6, 2026, and expected trading to commence on January 9, 2026 [1][5][6] - The company, founded in 2007, focuses on the research and development of small nucleic acid drugs, particularly siRNA therapies, with a core product RBD4059 targeting FXI for thrombotic diseases [7][10][21] - Rebio has a robust pipeline with seven self-developed drug assets in clinical trials, addressing cardiovascular, metabolic, renal, and liver diseases [9][10] Group 2 - The global small nucleic acid drug market is projected to grow significantly, with a compound annual growth rate (CAGR) of 21.6% from 2019 to 2024, and 29.4% from 2024 to 2029 [14] - The company utilizes its proprietary RiboGalSTAR™ platform for liver-targeted drug development, which enhances delivery efficiency and specificity [15][20] - Rebio has received five IND/CTA approvals from regulatory authorities in 2024, including four for Phase II clinical trials, indicating strong progress in its clinical development [16] Group 3 - RBD4059 is the first siRNA drug in clinical stages for treating thrombotic diseases, showing significant efficacy in reducing FXI activity by up to 91.6% in clinical trials [26] - The drug's long-acting formulation allows for administration every 3-6 months, potentially improving patient compliance compared to traditional anticoagulants [28] - RBD5044, targeting high triglycerides, is the second siRNA drug in clinical development, demonstrating strong triglyceride-lowering effects and good safety profiles [30][34] Group 4 - The company has established a global R&D center in Sweden, Ribocure AB, which includes a clinical trial unit (CTU) for conducting independent clinical trials [40] - Rebio has formed strategic partnerships with major pharmaceutical companies, including Boehringer Ingelheim, to enhance its growth prospects and leverage its siRNA technology [41]

Core Viewpoint - The company, Rebio Biotech-B (06938.HK), is planning a global offering of 27.4874 million H-shares, with a proposed price of HKD 57.97 per share, aiming to raise approximately HKD 1.4736 billion for various research and development initiatives [1][3]. Group 1: Offering Details - The company intends to issue 27.4874 million H-shares, with 2.7488 million shares available in Hong Kong and 24.7386 million shares for international offering, subject to adjustments [1]. - The subscription period for the shares is set from December 31, 2025, to January 6, 2026, with trading expected to commence on January 9, 2026 [1]. - The shares will be sold at a price of HKD 57.97 each, with a trading unit of 200 shares [1]. Group 2: Investment Agreements - The company has entered into cornerstone investment agreements, with investors agreeing to purchase shares totaling approximately USD 100 million (around HKD 778 million) at the offering price [2]. - The cornerstone investors include various entities such as Arc Avenue Asset Management, Bright Stone Holdings, and several funds and investment firms [2]. Group 3: Use of Proceeds - The estimated net proceeds of approximately HKD 1.4736 billion will be allocated as follows: - About 37.4% for the development of the core product RBD4059 - Approximately 19.6% for RBD5044 - Around 15.9% for RBD1016 - About 10.1% for funding preclinical trial stage assets - Approximately 8.9% for advancing preclinical assets not yet in trials - About 8.1% for working capital and general corporate purposes [3].

Core Viewpoint - The company, Ribocure AB, is set to launch an IPO with a global offering of 27.4874 million H-shares at a price of HKD 57.97 per share, aiming to raise approximately HKD 1.474 billion for its drug development pipeline, particularly focusing on siRNA therapies for various diseases [1][3]. Group 1: IPO Details - The IPO will take place from December 31, 2025, to January 6, 2026, with 10% of the shares allocated for the Hong Kong offering and 90% for international investors, including an overallotment option of 15% [1]. - The shares are expected to commence trading on the Hong Kong Stock Exchange on January 9, 2026 [1]. Group 2: Product Pipeline - Ribocure AB specializes in small nucleic acid drug research and development, particularly focusing on siRNA therapies, with a core product, RBD4059, targeting FXI for thrombotic disease treatment [1]. - The company has seven self-developed drug assets in clinical trials, addressing cardiovascular, metabolic, renal, and liver diseases, with four products currently in Phase 2 clinical trials [1]. - In addition to RBD4059, the company is advancing other clinical-stage products, including RBD5044, the second siRNA drug targeting APOC3 in clinical development globally, and RBD1016, aimed at achieving functional cure for chronic hepatitis B [1]. Group 3: Use of Proceeds - The estimated net proceeds of approximately HKD 1.474 billion from the global offering will be allocated as follows: 37.4% for RBD4059 development, 19.6% for RBD5044, 15.9% for RBD1016, 10.1% for preclinical assets, 8.9% for advancing preclinical projects, and 8.1% for working capital and general corporate purposes [3]. Group 4: Cornerstone Investors - The company has entered into cornerstone investment agreements with several investors, including Arc Avenue and Bright Stone, who have committed to subscribe for shares amounting to approximately USD 100 million, reflecting confidence in the company's business prospects [2].

智通财经APP讯，瑞博生物-B(06938)于2025年12月31日至2026年1月6日招股，公司拟全球发售2748.74 万股H股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价57.97港元，H 股将以每手200股H股为买卖单位，预计H股将于2026年1月9日(星期五)上午九时正在联交所开始买卖。 我们是一家从事小核酸药物研究和开发，尤其专注于siRNA疗法的生物制药公司。我们拥有一款用于治 疗血栓性疾病的核心产品RBD4059(靶向FXI 的siRNA)，研发管线中共有七款自研药物资产处于临床试 验阶段，涉及心血管、代谢类、肾脏和肝脏疾病的七种适应症，其中四款处于2期临床试验中。 除核心产品RBD4059外，我们还在推进其他临床阶段产品，包括RBD5044和 RBD1016。RBD5044是全 球第二款进入临床开发的靶向APOC3(一种参与脂质代谢的蛋白)的siRNA药物。RBD1016通过对HBsAg 的作用，旨在实现CHB的功能性治癒，同时也是一款针对CHD的差异化siRNA候选药物。在临床管线之 外，我们还拥有20多个临床前项目，计划将其推进至临床开发阶段。 我们与基石 ...

Group 1: Biopharmaceutical Research - The small nucleic acid drug industry is entering a new era with a focus on siRNA drugs for common diseases, driven by mature technology platforms and expanding indications [1][2] - siRNA drugs have transitioned from rare diseases to common diseases, showing strong commercial potential in areas like cardiovascular diseases and chronic hepatitis B [2][3] - The industry is witnessing active business development (BD) transactions, particularly involving Chinese companies leveraging their engineering advantages in small nucleic acid technology [3][4] Group 2: Automotive Research - Bertli's new "small diameter caliper technology" is expected to enhance its market share in the braking sector, aligning with the automotive industry's cost-reduction trends [6][30] - The company has received recognition for its innovative technology, which reduces vehicle weight by 4.4 kg (17% reduction), improving energy efficiency and vehicle handling [30][31] - Bertli is establishing a subsidiary focused on electric motor systems for chassis, aiming to strengthen its position in intelligent driving and robotics [31] Group 3: Food and Beverage Research - The expansion of domestic demand has been elevated to a strategic level, with the consumption sector expected to rebound [8][9] - The liquor sector, particularly Wuliangye, is targeting high-quality sales and market share growth for 2026, while the dairy industry is anticipated to experience a cyclical reversal [9][11] - Structural growth is expected in the beverage sector, with companies like Dongpeng Beverage and Nongfu Spring positioned for significant gains [11] Group 4: Transportation Research - 吉祥航空 is expected to see a gradual reduction in the impact of flight maintenance issues in 2026, with significant profit potential driven by industry recovery and fleet turnover [12][13] - The company has a robust network that is projected to yield substantial profits as the aviation market improves [12][28] - The introduction of the B787 aircraft is expected to enhance international operations, with optimistic long-term profitability forecasts [29]

长风药业(02652)发布公告，由公司主导的新型吸入式核酸药物开发项目近期获选为2025年江苏省科技 重大专项"创新生物药"项目。本项目聚焦于小核酸(siRNA)药物在肺部递送中的关键挑战，致力于推动 吸入式核酸候选药物的转化研究与临床前开发。 公司认为，本项目的入选对集团具有重要战略意义，进一步验证了集团技术平台的实力。递送技术是 siRNA肺部治疗的关键壁垒。对此，公司已自主研发出一套高效肺靶向递送系统，相关候选药物在临床 前研究中显示出良好的治疗潜力。本项目的入选，体现了相关部门及评审专家对公司与合作单位在前沿 递送技术领域联合研发能力的充分认可。公司将持续通过技术创新，致力于为患者提供更具价值的治疗 方案，并为股东创造可持续的长期回报。 本项目计划支持针对呼吸系统重大疾病(包括哮喘、慢性阻塞性肺病及肺纤维化)的吸入式核酸候选药物 研发工作。工作范围涵盖递送体系优化、药剂学与工艺开发、临床前研究，以及新药临床试验申请准 备。 ...

公司认为，本项目的入选对集团具有重要战略意义，进一步验证了集团技术平台的实力。递送技术是 siRNA肺部治疗的关键壁垒。对此，公司已自主研发出一套高效肺靶向递送系统，相关候选药物在临床 前研究中显示出良好的治疗潜力。本项目的入选，体现了相关部门及评审专家对公司与合作单位在前沿 递送技术领域联合研发能力的充分认可。公司将持续通过技术创新，致力于为患者提供更具价值的治疗 方案，并为股东创造可持续的长期回报。 本项目计划支持针对呼吸系统重大疾病(包括哮喘、慢性阻塞性肺病及肺纤维化)的吸入式核酸候选药物 研发工作。工作范围涵盖递送体系优化、药剂学与工艺开发、临床前研究，以及新药临床试验申请准 备。 智通财经APP讯，长风药业(02652)发布公告，由公司主导的新型吸入式核酸药物开发项目近期获选为 2025年江苏省科技重大专项"创新生物药"项目。本项目聚焦于小核酸(siRNA)药物在肺部递送中的关键 挑战，致力于推动吸入式核酸候选药物的转化研究与临床前开发。 ...

Group 1: siRNA Drug Development - The core viewpoint is that siRNA drugs are transitioning from rare diseases to common diseases, driven by technological upgrades and product approvals, marking a new era in targeted therapy [3][4] - siRNA drugs are characterized by strong target expansion capabilities, robust research extensibility, long-lasting effects, and low likelihood of developing resistance, making them a focus for domestic pharmaceutical companies [3][4] - Since 2016, with advancements in the GalNac delivery system and fully modified applications, siRNA drugs have entered a rapid development phase, validating their value in rare diseases and gradually moving towards common disease research [3][4] Group 2: Market Dynamics and Opportunities - The market for small nucleic acid drugs is heating up, with multinational corporations (MNCs) actively engaging in business development (BD) transactions, indicating a sustained interest in this field [4] - Chinese companies are expected to shine in this area due to their engineering advantages, particularly in chemical synthesis, allowing for rapid iteration on leading technologies [4] - The commercialization process of siRNA drugs is focused on common diseases with clear biological mechanisms, where early movers are likely to gain significant commercial benefits [5] Group 3: Industry Trends and Future Outlook - The efficiency and specificity of the GalNac delivery system present opportunities for breakthroughs in liver-targeted therapies and the exploration of previously challenging drug targets [5] - The industry is witnessing a shift towards addressing common diseases, with a focus on new disease areas and advancements in extrahaptic delivery systems [5] - The overall sentiment in the pharmaceutical sector is optimistic, with expectations of significant developments in the siRNA drug space, particularly in large indications such as cardiovascular diseases and chronic hepatitis B [3][4][5]

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Insights - The pharmaceutical sector is experiencing a phase of oscillation and differentiation, with a recommendation to seize thematic rotation and bottom adjustment opportunities, particularly in the innovative drug supply chain and AI+ sectors [6][13] - The long-term growth driver for the pharmaceutical sector is technological innovation, with key focuses on "continuation of policy benefits," "breakthroughs in frontier technologies," and "international BD transactions" [6][13] - The report highlights the potential of new generation CTLA-4 therapies that address toxicity issues, thereby unlocking market potential [7] Summary by Sections Industry Overview - The pharmaceutical industry comprises 499 listed companies with a total market value of 71,291.29 billion [2] - The industry is currently valued at 25.8 times PE based on 2025 earnings forecasts, with a premium of 10.2% over the overall A-share market [22] Market Dynamics - The report notes a 14.49% return for the pharmaceutical sector since the beginning of 2025, underperforming the CSI 300 index by 1.60 percentage points [19] - Recent market movements show a decline in the pharmaceutical sector, with specific segments like pharmaceutical commerce and medical devices showing positive growth [19][6] Key Recommendations - Focus on companies involved in innovative drug development and AI applications, such as 恒瑞医药 (Hengrui Medicine), 中国生物制药 (China National Pharmaceutical Group), and 康方生物 (Kangfang Biopharma) [6][13] - The report emphasizes the importance of addressing clinical pain points and enhancing safety in new generation immuno-oncology drugs [7] Notable Companies - The report recommends several companies for investment, including 康方生物 (Kangfang Biopharma), 药明合联 (WuXi AppTec), and 泰格医药 (Tigermed) [7][30] - It highlights the performance of specific stocks, noting that the average decline for 中泰医药 (Zhongtai Medicine) was 2.51% this month, while it outperformed the industry by 0.68% this week [29][30]